Company: ARWR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001628280-25-004634
Chunk: 14

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
— — 15,209 Exercise of stock options70 — 634 — — — 634 Common stock - restricted stock units vesting209 — — — — — — Pre-funded warrants917 1 24,999 — — — 25,000 Foreign currency translation adjustments— — — (106)— — (106)Unrealized gains on available-for-sale securities— — — (507)— — (507)Net loss— — — — (173,085)(2,133)(175,218)Balance at December 31, 2024125,572 $218 $1,846,842 $4,137 $(1,798,608)$3,486 $56,075 

CommonStockAmount ($)AdditionalPaid-InCapitalAccumulated Other Comprehensive LossAccumulatedDeficitNon-controlling InterestTotalBalance at September 30, 2023107,312 $200 $1,300,395 $(3,222)$(1,026,030)$15,819 $287,162 Stock-based compensation— — 19,694 — — — 19,694 Exercise of stock options34 — 267 — — — 267 Common stock - restricted stock units vesting154 — — — — — — Foreign currency translation adjustments— — — 58 — — 58 Unrealized losses on available-for-sale securities— — — 1,909 — — 1,909 Net loss— — — — (132,864)(2,512)(135,376)Balance at December 31, 2023107,500 $200 $1,320,356 $(1,255)$(1,158,894)$13,307 $173,714 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

3

Arrowhead Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows 

(in thousands)

(unaudited)

Three Months Ended December 31,20242023CASH FLOWS FROM OPERATING ACTIVITIES:Net loss$(175,218)$(135,376)Adjustments to reconcile net loss to net cash flow from operating activitiesStock-based compensation